Characterization of aberrant oncogenic signaling in non-small-cell lung cancer (NSCLC) has resulted in precision cancer medicine treatment approaches via tyrosine kinase inhibitors (TKIs) towards mutated epidermal growth-factor receptor (EGFR) or EML4-ALK fusions [10,11,12,13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.